Daily Dose of 5 mg Tadalafil Safely Improves Erectile Function and Liver Function Enzymes in Smokers

Background: Smokers are known to have a higher risk of erectile dysfunction. We examined how daily consumption of low-dose tadalafil affected erectile function and circulation in smokers and assessed the medication safety. Methods: Men aged over 20 years with current smoking status were selected to complete four weeks of treatment with 5 mg tadalafil daily. Erectile function was measured using the International Index of Erectile Function (IIEF), and additional tests included measuring various serum parameters, electrocardiogram, and nail capillary blood flow. Results: The IIEF scores, capillary blood flow, and serum liver function enzyme levels significantly improved. There were no reported adverse side effects. Conclusions: Smokers who were administered 5 mg tadalafil daily for four weeks had improved International Index of Erectile Function scores, dilated capillary vessels, and improved blood liver function enzyme levels; proving not only safety of usage and its effectiveness but also possible features that can indicate usages of the drug in other purposes.

erectile dysfunction; liver function; smokers; tadalafil

[1] Rahman MM, Laher I. Structural and Functional Alteration of Blood Vessels Caused by Cigarette Smoking: an Overview of Molecular Mechanisms. Current Vascular Pharmacology. 2007; 5: 276–292.

[2] Jeremy JY, Mikhailidis DP, Pittilo RM. Cigarette smoking and cardiovascular disease. Journal of the Royal Society of Health. 1995; 115: 289–295.

[3] Kamceva G, Arsova-Sarafinovska Z, Ruskovska T, Zdravkovska M, Kamceva-Panova L, Stikova E. Cigarette smoking and oxidative stress in patients with coronary artery disease. Open Access Macedonian Journal of Medical Sciences. 2016; 4: 636–640.

[4] Pourmand G, Alidaee MR, Rasuli S, Maleki A, Mehrsai A. Do cigarette smokers with erectile dysfunction benefit from stop-ping? A prospective study. BJU International. 2004; 94: 1310–1313.

[5] Karabakan M, Keskin E, Akdemir S, Bozkurt A. Effect of tadalafil 5mg daily treatment on the ejaculatory times, lower urinary tract symptoms and erectile function in patients with erectile dysfunction. International Brazilian Journal of Urology. 2017; 43: 317–324.

[6] Andersson K. PDE5 inhibitors - pharmacology and clinical ap-plications 20 years after sildenafil discovery. British Journal of Pharmacology. 2018; 175: 2554–2565.

[7] von Heesen M, Dold S, Müller S, Scheuer C, Kollmar O, Schilling MK, et al. Cilostazol improves hepatic blood perfu-sion, microcirculation, and liver regeneration after major hepa-tectomy in rats. Liver Transplantation. 2015; 21: 792–800.

[8] Wilkins MR, Wharton J, Grimminger F, Ghofrani HA. Phospho-diesterase inhibitors for the treatment of pulmonary hyperten-sion. European Respiratory Journal. 2008; 32: 198–209.

[9] NIH Consensus Conference. Impotence. NIH consensus devel-opment panel on impotence. Journal of the American Medical Association. 1993; 270: 83–90.

[10] Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKin-lay JB. Impotence and its Medical and Psychosocial Correlates: Results of the Massachusetts Male Aging Study. Journal of Urol-ogy. 1994; 151: 54–61.

[11] Bacon CG, Mittleman MA, Kawachi I, Giovannucci E, Glasser DB, Rimm EB. Sexual Function in Men Older than 50 Years of Age: Results from the Health Professionals Follow-up Study. Annals of Internal Medicine. 2003; 139: 161–168.

[12] Ayta IA, Mckinlay JB, Krane RJ. The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possi-ble policy consequences. BJU International. 1999; 84: 50–56.

[13] Araujo AB, Esche GR, Kupelian V, O’Donnell AB, Travison TG, Williams RE, et al. Prevalence of Symptomatic Andro-gen Deficiency in Men. Journal of Clinical Endocrinology and Metabolism. 2007; 92: 4241–4247.

[14] Yafi FA, Jenkins L, Albersen M, Corona G, Isidori AM, Goldfarb S, et al. Erectile dysfunction. Nature Reviews Disease Primers. 2016; 2: 16003.

[15] Corbin JD. Mechanisms of action of PDE5 inhibition in erectile dysfunction. International Journal of Impotence Research. 2004; 16: S4–S7.

[16] Toque HA, Teixeira CE, Priviero FB, Morganti RP, Antunes E, De Nucci G. Vardenafil, but not sildenafil or tadalafil, has calcium-channel blocking activity in rabbit isolated pulmonary artery and human washed platelets. British Journal of Pharma-cology. 2008; 154: 787–796.

[17] Toque HA, Priviero FBM, Teixeira CE, Claudino MA, Baracat JS, Fregonesi A, et al. Comparative Relaxing Effects of Silde-nafil, Vardenafil, and Tadalafil in Human Corpus Cavernosum: Contribution of Endogenous Nitric Oxide Release. Urology. 2009; 74: 216–221.

[18] Venneri MA, Giannetta E, Panio G, De Gaetano R, Gian-frilli D, Pofi R, et al. Chronic inhibition of PDE5 lim-its pro-inflammatory monocyte-macrophage polarization in streptozotocin-induced diabetic mice. PLoS ONE. 2015; 10: e0126580.

[19] Islam BN, Sharman SK, Hou Y, Bridges AE, Singh N, Kim S, et al. Sildenafil Suppresses Inflammation-Driven Colorectal Can-cer in Mice. Cancer Prevention Research. 2017; 10: 377–388.

[20] El-Naa MM, Othman M, Younes S. Sildenafil potentiates the antitumor activity of cisplatin by induction of apoptosis and in-hibition of proliferation and angiogenesis. Drug Design, Devel-opment and Therapy. 2016; 10: 3661–3672.

[21] Sandner P, Hütter J, Tinel H, Ziegelbauer K, Bischoff E. PDE5 inhibitors beyond erectile dysfunction. International Journal of Impotence Research. 2007; 19: 533–543.

[22] Frajese GV, Pozzi F, Frajese G. Tadalafil in the treatment of erectile dysfunction; an overview of the clinical evidence. Clin-ical Interventions in Aging. 2006; 1: 439–449.

[23] Fibbi B, Morelli A, Vignozzi L, Filippi S, Chavalmane A, De Vita G, et al. Characterization of Phosphodiesterase Type 5 Ex-pression and Functional Activity in the Human Male Lower Uri-nary Tract. Journal of Sexual Medicine. 2010; 7: 59–69.

[24] Houdart F, Girard-Nau N, Morin F, Voisin P, Vannier B. The regulatory subunit of PDE6 interacts with PACSIN in photore-ceptors. Molecular Vision. 2005; 11: 106–170.

[25] Cahill KB, Quade JH, Carleton KL, Cote RH. Identification of Amino Acid Residues Responsible for the Selectivity of Tadalafil Binding to Two Closely Related Phosphodiesterases, PDE5 and PDE6. Journal of Biological Chemistry. 2012; 287: 41406–41416.

[26] Porst H. IC351 (tadalafil, Cialis): update on clinical experience. International Journal of Impotence Research. 2002; 14: S57–S64.

[27] Nivison-Smith L, Zhu Y, Whatham A, Bui BV, Fletcher EL, Acosta ML, et al. Sildenafil alters retinal function in mouse car-riers of Retinitis Pigmentosa. Experimental Eye Research. 2014; 128: 43–56.

[28] Lee K, Yang Y, Wang Y, Hou M, Lee F, Lin H, et al. Acute administration of sildenafil enhances hepatic cyclic guanosine monophosphate production and reduces hepatic sinusoid re-sistance in cirrhotic patients. Hepatology Research. 2008; 38: 1186–1193.

[29] Halverscheid L, Deibert P, Schmidt R, Blum HE, Dunkern T, Pannen BH, et al. Phosphodiesterase-5 inhibitors have distinct effects on the hemodynamics of the liver. BMC Gastroenterol-ogy. 2009; 9: 69.

[30] Kloner RA. Cardiovascular Effects of the 3 Phosphodiesterase-5 Inhibitors Approved for the Treatment of Erectile Dysfunction. Circulation. 2004; 110: 3149–3155.